Selected research
Industry Research
Liver Diseases Therapeutics Drugs Industry Research Report 2026
Market perspective
The global Liver Diseases Therapeutics Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liver Diseases Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liver Diseases Therapeutics Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Liver Diseases Therapeutics Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liver Diseases Therapeutics Drugs include Achillion Pharmaceuticals, Angion Biomedica, F. Hoffmann-La Roche, Gilead Sciences, LG Life Sciences, Phenex Pharmaceuticals, ProMetic Life Sciences, Raptor Pharmaceuticals and Verva Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liver Diseases Therapeutics Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liver Diseases Therapeutics Drugs Market by Company
Achillion Pharmaceuticals
Angion Biomedica
F. Hoffmann-La Roche
Gilead Sciences
LG Life Sciences
Phenex Pharmaceuticals
ProMetic Life Sciences
Raptor Pharmaceuticals
Verva Pharmaceuticals
AbbVie
Bayer
GlaxoSmithKline
Merck
Johnson & Johnson
Shenzhen Kangtai Biological Products
Liver Diseases Therapeutics Drugs Segment by Type
Oral Liver Diseases Therapeutics Drugs
Injection Liver Diseases Therapeutics Drugs
Liver Diseases Therapeutics Drugs Segment by Application
Hospitals
Clinics
Other
Liver Diseases Therapeutics Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Diseases Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liver Diseases Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Diseases Therapeutics Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liver Diseases Therapeutics Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liver Diseases Therapeutics Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liver Diseases Therapeutics Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Liver Diseases Therapeutics Drugs
- Injection Liver Diseases Therapeutics Drugs
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Achillion Pharmaceuticals
- Angion Biomedica
- F. Hoffmann-La Roche
- Gilead Sciences
- LG Life Sciences
- Phenex Pharmaceuticals
- ProMetic Life Sciences
- Raptor Pharmaceuticals
- Verva Pharmaceuticals
- AbbVie
- Bayer
- GlaxoSmithKline
- Merck
- Johnson & Johnson
- Shenzhen Kangtai Biological Products
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liver Diseases Therapeutics Drugs Market Size (2021-2032)
- 2.2.2 Global Liver Diseases Therapeutics Drugs Sales (2021-2032)
- 2.2.3 Global Liver Diseases Therapeutics Drugs Market Average Price (2021-2032)
- 2.3 Liver Diseases Therapeutics Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Liver Diseases Therapeutics Drugs
- 2.3.3 Injection Liver Diseases Therapeutics Drugs
- 2.4 Liver Diseases Therapeutics Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liver Diseases Therapeutics Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liver Diseases Therapeutics Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Liver Diseases Therapeutics Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Liver Diseases Therapeutics Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Liver Diseases Therapeutics Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liver Diseases Therapeutics Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liver Diseases Therapeutics Drugs, Product Type & Application
- 3.8 Global Manufacturers of Liver Diseases Therapeutics Drugs, Established Date
- 3.9 Global Liver Diseases Therapeutics Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Achillion Pharmaceuticals
- 4.1.1 Achillion Pharmaceuticals Company Information
- 4.1.2 Achillion Pharmaceuticals Business Overview
- 4.1.3 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Achillion Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 4.1.5 Achillion Pharmaceuticals Recent Developments
- 4.2 Angion Biomedica
- 4.2.1 Angion Biomedica Company Information
- 4.2.2 Angion Biomedica Business Overview
- 4.2.3 Angion Biomedica Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Angion Biomedica Liver Diseases Therapeutics Drugs Product Portfolio
- 4.2.5 Angion Biomedica Recent Developments
- 4.3 F. Hoffmann-La Roche
- 4.3.1 F. Hoffmann-La Roche Company Information
- 4.3.2 F. Hoffmann-La Roche Business Overview
- 4.3.3 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F. Hoffmann-La Roche Liver Diseases Therapeutics Drugs Product Portfolio
- 4.3.5 F. Hoffmann-La Roche Recent Developments
- 4.4 Gilead Sciences
- 4.4.1 Gilead Sciences Company Information
- 4.4.2 Gilead Sciences Business Overview
- 4.4.3 Gilead Sciences Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gilead Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 4.4.5 Gilead Sciences Recent Developments
- 4.5 LG Life Sciences
- 4.5.1 LG Life Sciences Company Information
- 4.5.2 LG Life Sciences Business Overview
- 4.5.3 LG Life Sciences Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 LG Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 4.5.5 LG Life Sciences Recent Developments
- 4.6 Phenex Pharmaceuticals
- 4.6.1 Phenex Pharmaceuticals Company Information
- 4.6.2 Phenex Pharmaceuticals Business Overview
- 4.6.3 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Phenex Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 4.6.5 Phenex Pharmaceuticals Recent Developments
- 4.7 ProMetic Life Sciences
- 4.7.1 ProMetic Life Sciences Company Information
- 4.7.2 ProMetic Life Sciences Business Overview
- 4.7.3 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 ProMetic Life Sciences Liver Diseases Therapeutics Drugs Product Portfolio
- 4.7.5 ProMetic Life Sciences Recent Developments
- 4.8 Raptor Pharmaceuticals
- 4.8.1 Raptor Pharmaceuticals Company Information
- 4.8.2 Raptor Pharmaceuticals Business Overview
- 4.8.3 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Raptor Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 4.8.5 Raptor Pharmaceuticals Recent Developments
- 4.9 Verva Pharmaceuticals
- 4.9.1 Verva Pharmaceuticals Company Information
- 4.9.2 Verva Pharmaceuticals Business Overview
- 4.9.3 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Verva Pharmaceuticals Liver Diseases Therapeutics Drugs Product Portfolio
- 4.9.5 Verva Pharmaceuticals Recent Developments
- 4.10 AbbVie
- 4.10.1 AbbVie Company Information
- 4.10.2 AbbVie Business Overview
- 4.10.3 AbbVie Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AbbVie Liver Diseases Therapeutics Drugs Product Portfolio
- 4.10.5 AbbVie Recent Developments
- 4.11 Bayer
- 4.11.1 Bayer Company Information
- 4.11.2 Bayer Business Overview
- 4.11.3 Bayer Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Bayer Liver Diseases Therapeutics Drugs Product Portfolio
- 4.11.5 Bayer Recent Developments
- 4.12 GlaxoSmithKline
- 4.12.1 GlaxoSmithKline Company Information
- 4.12.2 GlaxoSmithKline Business Overview
- 4.12.3 GlaxoSmithKline Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GlaxoSmithKline Liver Diseases Therapeutics Drugs Product Portfolio
- 4.12.5 GlaxoSmithKline Recent Developments
- 4.13 Merck
- 4.13.1 Merck Company Information
- 4.13.2 Merck Business Overview
- 4.13.3 Merck Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Merck Liver Diseases Therapeutics Drugs Product Portfolio
- 4.13.5 Merck Recent Developments
- 4.14 Johnson & Johnson
- 4.14.1 Johnson & Johnson Company Information
- 4.14.2 Johnson & Johnson Business Overview
- 4.14.3 Johnson & Johnson Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Johnson & Johnson Liver Diseases Therapeutics Drugs Product Portfolio
- 4.14.5 Johnson & Johnson Recent Developments
- 4.15 Shenzhen Kangtai Biological Products
- 4.15.1 Shenzhen Kangtai Biological Products Company Information
- 4.15.2 Shenzhen Kangtai Biological Products Business Overview
- 4.15.3 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Shenzhen Kangtai Biological Products Liver Diseases Therapeutics Drugs Product Portfolio
- 4.15.5 Shenzhen Kangtai Biological Products Recent Developments
5 Global Liver Diseases Therapeutics Drugs Market Scenario by Region
- 5.1 Global Liver Diseases Therapeutics Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liver Diseases Therapeutics Drugs Sales by Region: 2021-2032
- 5.2.1 Global Liver Diseases Therapeutics Drugs Sales by Region: 2021-2026
- 5.2.2 Global Liver Diseases Therapeutics Drugs Sales by Region: 2027-2032
- 5.3 Global Liver Diseases Therapeutics Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Liver Diseases Therapeutics Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Liver Diseases Therapeutics Drugs Revenue by Region: 2027-2032
- 5.4 North America Liver Diseases Therapeutics Drugs Market Facts & Figures by Country
- 5.4.1 North America Liver Diseases Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 5.4.3 North America Liver Diseases Therapeutics Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Liver Diseases Therapeutics Drugs Market Facts & Figures by Country
- 5.5.1 Europe Liver Diseases Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Liver Diseases Therapeutics Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Liver Diseases Therapeutics Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liver Diseases Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liver Diseases Therapeutics Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liver Diseases Therapeutics Drugs Market Facts & Figures by Country
- 5.7.1 South America Liver Diseases Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 5.7.3 South America Liver Diseases Therapeutics Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Liver Diseases Therapeutics Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liver Diseases Therapeutics Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liver Diseases Therapeutics Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liver Diseases Therapeutics Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Liver Diseases Therapeutics Drugs Sales by Type (2021-2032)
- 6.1.1 Global Liver Diseases Therapeutics Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Liver Diseases Therapeutics Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Liver Diseases Therapeutics Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Liver Diseases Therapeutics Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liver Diseases Therapeutics Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Liver Diseases Therapeutics Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liver Diseases Therapeutics Drugs Sales by Application (2021-2032)
- 7.1.1 Global Liver Diseases Therapeutics Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Liver Diseases Therapeutics Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Liver Diseases Therapeutics Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Liver Diseases Therapeutics Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liver Diseases Therapeutics Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Liver Diseases Therapeutics Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liver Diseases Therapeutics Drugs Value Chain Analysis
- 8.1.1 Liver Diseases Therapeutics Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liver Diseases Therapeutics Drugs Production Mode & Process
- 8.2 Liver Diseases Therapeutics Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liver Diseases Therapeutics Drugs Distributors
- 8.2.3 Liver Diseases Therapeutics Drugs Customers
9 Global Liver Diseases Therapeutics Drugs Analyzing Market Dynamics
- 9.1 Liver Diseases Therapeutics Drugs Industry Trends
- 9.2 Liver Diseases Therapeutics Drugs Industry Drivers
- 9.3 Liver Diseases Therapeutics Drugs Industry Opportunities and Challenges
- 9.4 Liver Diseases Therapeutics Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst